Man Group plc Invests $6 Million in Twist Bioscience Corporation $TWST

Man Group plc bought a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 58,295 shares of the company’s stock, valued at approximately $5,997,000. Man Group plc owned 0.09% of Twist Bioscience at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in TWST. Quarry LP purchased a new stake in shares of Twist Bioscience in the third quarter worth about $28,000. Western Wealth Management LLC purchased a new position in Twist Bioscience during the 1st quarter valued at approximately $31,000. Strs Ohio purchased a new position in Twist Bioscience during the 1st quarter valued at approximately $33,000. Strategic Advocates LLC increased its stake in Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after acquiring an additional 906 shares during the last quarter. Finally, SBI Securities Co. Ltd. increased its stake in Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after acquiring an additional 571 shares during the last quarter.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $141.38 on Friday. The firm has a market cap of $8.87 billion, a P/E ratio of -63.68 and a beta of 2.14. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $155.44. The stock’s fifty day moving average price is $106.95 and its 200-day moving average price is $73.82.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.Twist Bioscience’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.33 EPS. On average, equities research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Leerink Partners set a $110.00 price target on Twist Bioscience in a research report on Thursday, July 16th. Guggenheim reissued a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 24th. Barclays upped their price objective on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Finally, Robert W. Baird raised their price objective on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $98.30.

Insiders Place Their Bets

In related news, CEO Emily M. Leproust sold 41,570 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $151.98, for a total value of $6,317,808.60. Following the transaction, the chief executive officer directly owned 770,729 shares of the company’s stock, valued at $117,135,393.42. This represents a 5.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 2,399 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $94.33, for a total value of $226,297.67. Following the completion of the transaction, the chief financial officer directly owned 110,276 shares in the company, valued at $10,402,335.08. This represents a 2.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 193,099 shares of company stock worth $24,026,581 over the last quarter. Company insiders own 3.08% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.